ANPCY News and Press, Angle Plc Surrey ADR From 05/31/19

Analytical studies ongoing to support FDA submission GUILDFORD, SURREY / ACCESSWIRE / May 31, 2019 / ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, is delighted to announce positive results from its Parsortix FDA clinical study for metastatic breast cancer. T...

BREAKTHROUGH RESEARCHUSING THE PARSORTIX SYSTEM DISCOVERS ROLE OF BODY'S OWN IMMUNE SUPPRESSOR CELLSIN PROMOTING CANCER METASTASIS Research using Parsortixdiscovers large CTC clusters of 10-30 cells comprising both cancer cells andimmune suppressor cells, which dramatically increas...

MD Anderson Develops New Technique For Assessing Cancer UsingParsortix Study published in leading peer-reviewed publication Nature GUILDFORD, SURREY / ACCESSWIRE / April 18, 2019 / ANGLE plc (AIM: AGL) (OTCQX: ANPCY), a world-leading liquid biopsy company, is pleased to announce th...

Leading ANGLE Customer Has Established A Multi-Centre Study Using Parsortix Seeking to Identify Markers for Early Prediction of Cancer Relapse in Non Small Cell Lung Cancer GUILDFORD, SURREY / ACCESSWIRE / April 12, 2019 / ANGLE plc (the "Company") (AIM: AGL OTCQX: ANPCY), a world-leadi...

Angle's Parsortix System Showcased in Six Poster Presentations at Leading Cancer Conference AACR 2019 Customers publish data from four independent studies demonstrating success with ANGLE's Parsortixliquid biopsy system ANGLE publishes detailed analytical performance data of ...

GUILDFORD, SURREY / ACCESSWIRE / March 11, 2019 / ANGLE plc (AIM: AGL OTCQX: ANPCY). TR-1: Standard form for notification of majorholdings This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct A...

GUILDFORD, SURREY / ACCESSWIRE / March 7, 2019 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that enrolment for its Parsortix FDA clinical study for metastatic breast cancer is now complete. We are grateful to the four leading US cancer c...

FIRST SUBJECTS ENROLLED IN OVARIAN CANCER CLINICAL VERIFICATION STUDY Study to confirm the combination of ANGLE's Parsortix system with its new HyCEAD Ziplex platform as sample-to-answer for accurate pelvic mass triage Study expected to complete in Q1 CY2020 GUILDFORD, SURRE...

LEADING CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX RESULTING IN A 30-FOLD INCREASE IN HARVESTED CANCER CELLS FOR ANALYSIS Viable cancer cells harvested from diagnostic leukapheresis (DLA) samples for key downstream processes such as in vitro culture Success achieved wit...

New CTC cluster researchpublished in prestigious nature publication f urther demonstrates theimportant role for Parsortix in enabling breakthrough developments in thetreatment of cancer. GUILDFORD, SURREY / ACCESSWIRE / February 11, 2019 / ANGLE plc (AIM: AGL OTCQX: ANPCY),...